Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction: Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program
Top Cited Papers
Open Access
- 27 April 2006
- journal article
- research article
- Published by Elsevier
- Vol. 47 (10) , 1997-2004
- https://doi.org/10.1016/j.jacc.2006.01.060
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAmerican Heart Journal, 2006
- Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)American Heart Journal, 2005
- Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMETEuropean Heart Journal, 2005
- Effect of Candesartan on Cause-Specific Mortality in Heart Failure PatientsCirculation, 2004
- Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure SurveyEuropean Heart Journal, 2004
- Outcomes in heart failure patients with preserved ejection fractionJournal of the American College of Cardiology, 2003
- Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failureEuropean Heart Journal, 2000
- Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and designJournal of Cardiac Failure, 1999
- Effect of an irregular ventricular rhythm on cardiac outputThe American Journal of Cardiology, 1996
- Improving survival for patients with advanced heart failure: A study of 737 consecutive patientsJournal of the American College of Cardiology, 1995